Q-omics provides the consensus-scored TFRC profile across patient tissues and cancer cell-line models. TFRC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TFRC is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TFRC protein abundance shows 26,313 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, BLCA, and LSCC as cancer lineages where TFRC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFRC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFRC survival associations across molecular data types. TFRC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFRC RNA expression–survival associations across cancer types. High TFRC expression shows unfavorable associations in KIRP, CESC, THCA, KICH, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TFRC RNA expression.
This table summarizes TFRC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TFRC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFRC shows lower tumor expression in THCA and LUAD and higher tumor expression in BLCA, HNSC, LIHC and STAD. The BLCA box plot shows higher TFRC RNA expression in tumor versus normal tissue (log2 FC = +2.830, t-test p < 0.001).
This table shows molecular features associated with TFRC in patient tissues and cancer cell lines. In patient samples, TFRC shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TFRC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and PANCREAS.
